arrow
J

Jeffrey L. Probstfield

university of washington
H指数:65
被引数:2.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Global Variations in Heart Failure Etiology, Management, and Outcomes
2023-05-1644
OA
Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial

杜拉鲁肽与有和没有心力衰竭的患者的心血管和心力衰竭结局: 来自REWIND随机试验的事后分析

2022-09-2017
PRE
A novel kidney disease index reflecting both the albumin-to-creatinine ratio and estimated glomerular filtration rate, predicted cardiovascular and kidney outcomes in type 2 diabetes
2022-08-2210
OAAI
Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial
2022-04-213
OA
Risk Estimates of Imminent Cardiovascular Death and Heart Failure Hospitalization Are Improved Using Serial Natriuretic Peptide Measurements in Patients With Coronary Artery Disease and Type 2 Diabetes
2022-04-197
OAAI
Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial

慢性冠状动脉或外周动脉疾病患者长期使用利伐沙班和阿司匹林联合治疗: COMPASS试验开放标签扩展期间的结果

2022-04-0618
OA
Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trial
2022-01-248
PRE
Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis

在REWIND trail中使用杜拉鲁肽治疗的2型糖尿病和心血管危险因素患者的总心血管或致命事件: 事后分析

2020-11-2519
OAAI
Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin
2020-11-1620
PREAI
Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline The COMPASS MRI Substudy
STROKE
IF8.9
2020-10-0117
OAAI